Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.

Article Details

Citation

Bigoloni A, Gianotti N, Spagnuolo V, Galli L, Nozza S, Cossarini F, Salpietro S, Carini E, Piatti P, Vinci C, Lazzarin A, Castagna A

Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.

AIDS. 2012 Sep 10;26(14):1837-40. doi: 10.1097/QAD.0b013e32835705dd.

PubMed ID
22739393 [ View in PubMed
]
Abstract

Thirty-nine HIV-1-infected patients treated for 156 weeks with a new nucleoside analogue-sparing regimen [raltegravir, etravirine and maraviroc (REM) or raltegravir, etravirine and darunavir/ritonavir (RED)] showed a uniform increase in fasting glucose levels and a uniform decrease in insulin secretory capacity. Diabetes mellitus occurred in one RED-treated and four REM-treated patients. A worsening glucose tolerance was observed in highly treatment-experienced HIV-infected patients receiving effective antiretroviral therapy after virological failure.

DrugBank Data that Cites this Article

Pharmaco-metabolomics
DrugDrug GroupsMetaboliteChangeDescription
EtravirineApprovedGlucose
increased
Etravirine increases the level of Glucose in the blood
RaltegravirApprovedGlucose
increased
Raltegravir increases the level of Glucose in the blood
RitonavirApproved InvestigationalGlucose
increased
Ritonavir increases the level of Glucose in the blood